A Rapid, Digital Test for Detecting Non-Small Cell Lung Cancer

ChromaCode has developed an innovative high-definition PCR assay with cloud-based analysis for enhanced multiplexing and detection of biomarkers to guide targeted therapies in the most common cancer of the lung, non-small cell lung cancer (NSCLC), which currently has a 5-year survival rate of only 25.4%. Unfortunately, just 50% of patients undergo timely testing of driver mutations to facilitate targeted treatment. Cost, lack of local testing facilities, slow turnaround time, and insufficient or poor-quality tissue samples are the primary obstacles. The ChromaCode assay can help: turnaround time was a mere 3 hours, results were highly concordant with next-generation sequencing (NGS), and information was rescued from multiple samples that had input too low for NGS.

Lung Cancers Today spoke with Mark McDonough, CEO of ChromaCode, to find out more about this innovative technology that may help patients with lung cancer.